773108-64-8

Basic information

• Product Name: 4-Amino-2,5-Difluorobenzoic Acid
• Synonyms: 4-Amino-2,5-Difluorobenzoic Acid;Benzoic acid, 4-aMino-2,5-difluoro-
• CAS NO: 773108-64-8
• Molecular Formula: C₇H₅F₂NO₂
• Molecular Weight: 173.1169064
• Product Categories: Fluorin-contained Benzoic acid series
• Mol File: 773108-64-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 316℃
• Flash Point: 145℃
• Appearance: /
• Density: 1.536
• Vapor Pressure: 0.000172mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.59±0.10(Predicted)
• CAS DataBase Reference: 4-Amino-2,5-Difluorobenzoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-2,5-Difluorobenzoic Acid(773108-64-8)
• EPA Substance Registry System: 4-Amino-2,5-Difluorobenzoic Acid(773108-64-8)

Safety Data

• Hazardous Substances Data: 773108-64-8(Hazardous Substances Data)

Usage

General Description

4-Amino-2,5-Difluorobenzoic Acid is a chemical compound with the molecular formula C7H5F2NO2. It is a derivative of benzoic acid and contains two fluorine atoms and an amino group. 4-Amino-2,5-Difluorobenzoic Acid is primarily used as a building block in the synthesis of pharmaceutical drugs and agrochemicals. It is also used in research and development as a reagent in organic chemistry reactions. Additionally, it has been studied for potential applications in materials science and as a component in the development of new drug candidates. Overall, 4-Amino-2,5-Difluorobenzoic Acid is a versatile and important chemical compound with various industrial and scientific applications.

InChI:InChI=1/C7H5F2NO2/c8-4-2-6(10)5(9)1-3(4)7(11)12/h1-2H,10H2,(H,11,12)

Upstream product

• 112279-60-4 4-bromo-2,5-difluoroaniline 
• 98349-22-5 2,4,5-trifluorobenzonitrile 
• 112279-61-5 4-amino-2,5-difluoro-benzonitrile 
• 116465-48-6 2,5‐difluoro‐4‐nitrobenzoic acid 

Downstream Products

• 952285-52-8 methyl 4-amino-2,5-difluorobenzoate 
• 1346764-05-3 ethyl 4-amino-2,5-difluorobenzoate 
• 1346764-06-4 4-amino-2,5-difluorophenylmethanol 
• 1124213-74-6 N-tert-butyl-3-((4-(4-(3-cyclobutylureido)-2,5-difluorobenzoyl)piperazin-1-yl)methyl)-benzamide 
• 1001347-60-9 4-amino-2,5-difluoro-N-[[1-(pyrrolidin-1-ylmethyl)cyclopropyl]methyl]benzamide 
• 1001347-30-3 4-amino-2,5-difluoro-N-[(3R)-1-methylpyrrolidin-3-yl]benzamide 
• 1001347-65-4 4-amino-2,5-difluoro-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]non-7-yI]benzamide 
• 1124213-76-8 3-((4-(4-amino-2,5-difluorobenzoyl)piperazin-1-yl)methyl)-N-tert-butylbenzamide 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment

Human dihydroorotate dehydrogenase (hDHODH), as the fourth and rate-limiting enzyme of the de novo pyrimidine synthesis pathway, is regarded as an attractive target for malignancy therapy. In the present study, a novel series of teriflunomide derivatives were designed, synthesized, and evaluated as hDHODH inhibitors. 13t was the optimal compound with promising enzymatic activity (IC50 = 16.0 nM), potent antiproliferative activity against human lymphoma Raji cells (IC50 = 7.7 nM), and excellent aqueous solubility (20.1 mg/mL). Mechanistically, 13t directly inhibited hDHODH and induced cell cycle S-phase arrest in Raji cells. The acute toxicity assay indicated a favorable safety profile of 13t. Notably, 13t displayed significant tumor growth inhibition activity with a tumor growth inhibition (TGI) rate of 81.4% at 30 mg/kg in a Raji xenograft model. Together, 13t is a promising inhibitor of hDHODH and a preclinical candidate for antitumor therapy, especially for lymphoma.

NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

N-BENZYL, N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS

The present invention relates to N-benzyl,N'-arylcarbonylpiperazine derivatives having the general Formula (I) to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N'-arylcarbonylpiperazine derivatives for the manufacture